(Q48513500)

12 February 2018

title

Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. (English)

1 reference

12 February 2018

author

Jonathan D. Cooper

3

1 reference

12 February 2018

author name string

Brian R Vuillemenot

1

1 reference

12 February 2018

Derek Kennedy

2

1 reference

12 February 2018

Andrew M S Wong

4

1 reference

12 February 2018

Sarmi Sri

5

1 reference

12 February 2018

Thom Doeleman

6

1 reference

12 February 2018

Martin L Katz

7

1 reference

12 February 2018

Joan R Coates

8

1 reference

12 February 2018

Gayle C Johnson

9

1 reference

12 February 2018

Randall P Reed

10

1 reference

12 February 2018

Eric L Adams

11

1 reference

12 February 2018

Mark T Butt

12

1 reference

12 February 2018

Donald G Musson

13

1 reference

12 February 2018

Joshua Henshaw

14

1 reference

12 February 2018

Steve Keve

15

1 reference

12 February 2018

Rhea Cahayag

16

1 reference

12 February 2018

Laurie S Tsuruda

17

1 reference

12 February 2018

Charles A O'Neill

18

1 reference

12 February 2018

publication date

16 September 2014

1 reference

12 February 2018

Molecular Genetics and Metabolism

published in

1 reference

12 February 2018

volume

114

1 reference

12 February 2018

issue

2

1 reference

12 February 2018

page(s)

281-293

1 reference

12 February 2018

A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Preclinical models used for immunogenicity prediction of therapeutic proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Recent insights into a new hydrodynamics of the cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Morphologic changes associated with intrathecal catheters for direct delivery to the central nervous system in preclinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin-like growth factor-1 treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Maturation of human tripeptidyl-peptidase I in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

The efficiency of systematic sampling in stereology and its prediction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Neuronal ceroid lipofuscinoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

The function and structure of the cerebrospinal fluid outflow system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2014.09.004

10.1016/J.YMGME.2014.09.004

7 January 2021

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018